Singer Jaheim to appear in Fulton County court after animal cruelty arrest
R&B singer Jaheim is expected to appear in court on Monday for a plea hearing after he was charged with six counts of animal cruelty.
Court documents accuse the singer of failing to provide adequate food, water, sanitary conditions, and ventilation for six dogs.
The Grammy-nominated singer was arrested on similar charges at his home in New Jersey in 2021.
FULTON COUNTY, Ga. - Grammy-nominated R&B singer Jaheim is expected in court on Monday in Fulton on animal cruelty charges.
Court records show that the singer, known for his hits like "Just in Case" and "Anything," was arrested in early May and is facing six counts of animal cruelty.
What we know
Jaheim, whose given name is Jaheim Hoagland, is accused of failing to provide adequate food, water, sanitary conditions, and ventilation for six dogs.
The documents identify the dogs as Tweet, Tip, Taka, Tink, Timber, and Tanger - four pit bull terriers, a French bulldog, and a mixed-breed hound.
According to NBC News, Fulton County Animal Control officers first responded to a call on April 27 about a dog in the back of an RV parked at a shopping mall that appeared to be malnourished.
When animal control officers came back with the police the next day, the singer reportedly took out the animals. The affidavit described the dog as appearing to be ""severely emaciated" with his rib cage "protruding through the skin," NBC reports.
After receiving more reports of additional dogs appearing emaciated, the officers found the singer's RV at another location and arrested him.
Hoagland was released from custody a day after his arrest.
Dig deeper
This is not the first time the singer has been arrested and charged with animal cruelty.
According to Complex, Hoagland was taken into custody at his home in New Jersey in 2021 after authorities found over a dozen dogs allegedly living in unsafe and unsanitary conditions. At least one dog has to be euthanized, officials say.
What's next
A plea hearing is set for Hoagland on Monday in Fulton County.
The Source
Information for this story was taken from documents from the State Court of Fulton County obtained by FOX 5 and reports from Complex and NBC News.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
UPI
25 minutes ago
- UPI
Clinical trial shows promise for new pancreatic cancer vaccine
A small clinical trial suggests a new vaccine aimed at a common cancer gene mutation could help stop aggressive pancreatic cancers from coming back. File Photo by Debbie Hill/UPI | License Photo A new vaccine aimed at a common cancer gene mutation could help stop aggressive pancreatic cancers from coming back, a small clinical trial suggests. Pancreatic cancer is one of the most lethal cancers, with a five-year survival rate of about 13%, according to the American Cancer Society. Further, up to 80% of cases return after treatment, the National Institutes of Health says. "If you were to ask me what disease most needs something to prevent recurrences, I'd say this one," Dr. Zev Wainberg, a leader of the trial, told NBC News. He's co-director of the University of California, Los Angeles gastrointestinal oncology program. The experimental vaccine targets KRAS gene mutations, which are found in about 25% of all cancers, the University of Texas MD Anderson Cancer Center says. This includes up to 90% of pancreatic cancers and roughly 40% of colon cancers. While these mutations have long been considered impossible to treat with drugs, researchers are finding new ways to target them. The vaccine, called ELI-002 2P, uses small chains of amino acids called peptides to train the immune system to spot and destroy cells with KRAS mutations. Unlike many cancer vaccines that are custom-made for each patient, this one is designed to be off the shelf, meaning it doesn't require the tumor to be sequenced before it's used, NBC News reported. The Phase 1 study -- reported Tuesday in Nature Medicine -- included 20 people with pancreatic cancer and five with colon cancer. All had KRAS mutations and had already undergone surgery and chemotherapy. Blood tests after surgery showed microscopic evidence of residual disease - cancer cells too small to see on scans. These leftover cells can cause the cancer to spread and return. Post-surgery, participants received up to six priming doses of the vaccine, with 13 also getting booster shots. In all, the process took six months. Here's what the results showed: 85% (21 of 25 participants) had an immune response to the KRAS mutations. About two-thirds of those had a strong enough response to help clear lingering cancer cells. Nearly 70% developed immunity to other tumor targets not included in the vaccine. A few "super-responders" had exceptionally strong immune reactions and the best outcomes. In the pancreatic cancer group, patients survived for an average of 29 months, staying recurrence-free for more than 15 months after vaccination. "That far exceeds the rates with resectable [surgically removable] cancers," Wainberg said. Cancer vaccines have been difficult to create because cancer cells share many proteins with healthy cells, making safe targets hard to find. Advances in mRNA technology and faster gene sequencing are now making more effective cancer vaccines possible. The peptides in this vaccine also have a unique "tail" that helps them stay in lymph nodes, where immune cells are activated -- a feature past peptide vaccines didn't have, said Stephanie Dougan, an associate professor at Dana-Farber Cancer Institute in Boston, who was not involved in the study. More research is needed to confirm the findings, and a Phase 2 trial is now underway to compare the vaccine with standard care. "The fact that the long-term survival really correlated with T-cell response suggests that the vaccine caused this," Dougan said, referring to the specific immune cells activated by the vaccine. "The idea that you can target KRAS is really exciting." More information The Mayo Clinic has more on pancreatic cancer. Copyright © 2025 HealthDay. All rights reserved.
Politico
an hour ago
- Politico
Bhattacharya and Kennedy split on mRNA cuts
AROUND THE AGENCIES National Institutes of Health Director Jay Bhattacharya is making the case that mRNA vaccine technology is 'promising, but not yet ready for prime time.' He cites a lack of public trust in the technology as the reason his boss, Health Secretary Robert F. Kennedy Jr.,recently canceled $500 million in mRNA vaccine development projects. Bhattacharya weighed in on Kennedy's decision in a conversation over the weekend with Steve Bannon, the longtime Trump ally and prominent MAGA figure, on Bannon's 'War Room' podcast: 'The reason that he did that — and I think it's very important for people to understand — as far as public health goes for vaccines, the mRNA platform is no longer viable,' Bhattacharya said. 'You can't have a platform where such a large fraction of the population distrusts the platform, if you're going to use it for vaccines, and expect it to work.' But, but, but: Kennedy, who has long been suspicious of the mRNA vaccine platform, offered an explanation for the funding cuts that contradicts Bhattacharya's reasoning. 'After reviewing the science and consulting top experts at NIH and FDA, HHS has determined that mRNA technology poses more risk than benefits for these respiratory viruses,' Kennedy said in a video posted on social media last week, referring to Covid-19 and flu mRNA vaccines. Big picture: Scientists and drugmakers worry that Kennedy's skepticism of mRNA could stifle cancer treatment developments, our Lauren Gardner reports. mRNA technology can instruct the immune system to attack problem proteins, so it holds promise as a customized treatment for rare cancers and diseases. As such, dozens of mRNA therapies are being studied or are in the drug-development pipeline. Bhattacharya seemed aware of the technology's use beyond flu and Covid vaccines. After telling Bannon that mRNA technology wasn't ready for widespread vaccine use, he added: 'For cancer, maybe it's another story.' WELCOME TO FUTURE PULSE This is where we explore the ideas and innovators shaping health care. A swarm of jellyfish shut down reactors at a French nuclear power station, Ketrin Jochecová, our POLITICO colleague in Europe, reports. Share any thoughts, news, tips and feedback with Ruth Reader at rreader@ or Erin Schumaker at eschumaker@ Want to share a tip securely? Message us on Signal: RuthReader.02 or ErinSchumaker.01. OPERATING ROOM A large-scale study of New York's Mount Sinai Health System suggests that artificial intelligence could help emergency departments better handle their patient loads. In the study, researchers from Mount Sinai trained an AI model on 1.8 million emergency department visits between January 2019 and December 2023. Then they tested the model by comparing it with two months' worth of nurse triage assessments of nearly 50,000 patient visits across the system's urban and suburban hospitals. The result: Nurse predictions were 81.6 percent accurate, while the AI model's assessments were 85.4 percent accurate. The study, published in the journal Mayo Clinic Proceedings: Digital Health in July, had a few limitations, the authors noted, including that the research was conducted at a single health system over a short time span. Outcomes might differ in another setting, and longer-term trends could yield different results. Bird's eye view: 'The strength of this approach is its ability to turn complex data into timely, actionable insights for clinical teams — freeing them up to focus less on logistics and more on delivering the personal, compassionate care that only humans can provide,' Dr. Eyal Klang, study co-author and director of the Generative AI Research Program at Mount Sinai, said in a statement.
New York Post
2 hours ago
- New York Post
American hiker found dead in Spain weeks after vanishing while on solo trek
An American hiker has been found dead in a national park in Spain — weeks after the 27-year-old vanished on a solo trek. Cole Henderson's body was located Friday in the Pyrenees mountain region, which straddles the border of Spain and France, authorities said. Missing hiker, Cole Henderson, was found dead in the Pyrenees mountain region of Spain. Facebook/Eric Simon The 27-year-old worked as an engineer in Amsterdam. Facebook/Eric Simon Search teams found his remains some 650 feet down a difficult-to-access part of the north face of Monte Perdido. Henderson was last heard from on July 9 after he set off on the hike by himself, NBC News reported. He was reported missing five days later when he failed to return to his home in Amsterdam, where he'd been working as an engineer.
